About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
Role of Genomics in Multiple Myeloma
By
Houston Methodist Hospital
FEATURING
Nikhil Munshi
October 5, 2022
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
23:00
Total Health
ctDNA and MRD: Who, What, and Then What?
Feat.
A. Parikh
09:48
ecancer
ESMO 2022 on the PATHFINDER Study: A New Era of Early Cancer Detecti…
Feat.
D. Schrag
20:31
Total Health
Diagnostics: Genomics for Treatment Planning of Breast Cancer
Feat.
R. L. Mahtani
05:56
ASH 2022 Conference Coverage
ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…
Feat.
G. Morgan
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
08:04
ASCO 2022 Conference Coverage
ASCO 2022 on OPTIMA Preliminary Trial: Disparity Between Ki67 Measur…
Feat.
R. Stein
04:31
ASH 2022 Conference Coverage
ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …
Feat.
A. Chari
15:54
Paul Richardson
Emerging Strategies in the Management of Relapsed MM
30:59
Houston Methodist Hospital
Overview of Advances in Multiple Myeloma
Feat.
S. Ganguly
09:09
Douglas W. Sborov
IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…
34:48
Kenneth Anderson
MM Cured in 2030 - What Are the Next Steps?
Feat.
K. Anderson
21:38
Rahul Banerjee
CAR-T Therapy in Myeloma: What's Here and What's Coming So…
06:58
Saurabh Chhabra
Summary of the MAMMOTH Trial in R/R Myeloma
21:10
CancerGRACE
Tissue Genotyping: Challenges and Best Practices - Optimal NGS Platf…
Feat.
J. Weiss
10:08
ASH 2022 Conference Coverage
ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…
Feat.
N. Korde
06:41
Hamza Hashmi
Idecabtagene Vicleucel vs. Ciltacabtagene Autoleucel: A Sophie'…
21:16
UChicago Medicine
Myeloma 2022: Challenges and Path Forward
Feat.
A. Jakubowiak
10:09
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Next Questions for MM in the Coming 5-10 Years
Feat.
T. Martin
24:19
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…
Feat.
P. Richardson
